[Therapeutic effects of oral dipyridamole on myocardial perfusion and left ventricular function in patients with hypertrophic cardiomyopathy].
As myocardial ischemia possibly due to small vessel coronary disease has been reported in hypertrophic cardiomyopathy (HCM), we investigated therapeutic efficacy of oral dipyridamole (DP) in 20 patients. DP of 150 mg/day for 2 weeks significantly increased septal washout rate (39 +/- 14 to 45 +/- 11%) in exercise Tl-201 myocardial imaging, improving reversible defects in 6 patients. The result further supported that small vessel coronary disease could induce myocardial ischemia in HCM. In RI angiography. DP increased ejection fraction (50 +/- 9 to 53 +/- 7%) and peak filling rate (1.9 +/- 0.6 to 2.0 +/- 0.5 sec-1) at rest. DP also improved subjective symptoms, cardiac size and atrial premature beats in Holter monitoring. In exercise test, maximal work load was increased from 7.6 +/- 2.0 to 8.3 +/- 1.4 METS. These observations indicate that oral DP is an useful drug for treatment of HCM, in improving subjective symptoms, left ventricular function, exercise tolerance and arrhythmias, possibly due to beneficial effects on myocardial perfusion and afterload reduction.
Kihara
K
K
Third Department of Medicine, Kurume University School of Medicine.
D000284:Administration, Oral; D000328:Adult; D002312:Cardiomyopathy, Hypertrophic / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003326:Coronary Circulation / Q000187:drug effects*; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use*; D005080:Exercise Test; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging / Q000503:physiopathology*; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011875:Radionuclide Angiography; D013794:Thallium Radioisotopes
D013794:Thallium Radioisotopes; D004176:Dipyridamole